Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Glaxosmithkline plc symbols : Cvac save search
CureVac veröffentlicht Finanzergebnisse für das dritte Quartal sowie die ersten neun Monate 2023 und informiert über seine Geschäftsentwicklung
Published: 2023-11-14 (Crawled : 12:00) - curevac.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.12%
H: 0.14%
C: -0.49%
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: 3.45%
H: 4.56%
C: -0.7%
Global mRNA Vaccine Market Research Report 2023-2028: COVID-19 Success Opens New Avenues with with 444 Ongoing Clinical Studies Worldwide
Published: 2023-11-08 (Crawled : 03:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 1.91%
H: 0.0%
C: 0.0%
VERV | $6.66 -1.19% -1.2% 1.2M
|
Professional, Scientific, and T...
|
| O: 0.37%
H: 0.64%
C: -10.76%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.46%
H: 0.46%
C: -0.23%
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: -0.01%
H: 0.03%
C: -3.14%
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: 0.91%
H: 1.08%
C: -1.44%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: 0.13%
H: 0.08%
C: -2.81%
ARCT 4 | $26.31 -4.81% -5.06% 610K
|
Health Technology
|
| O: -0.36%
H: 0.79%
C: -0.61%
covid-19 success report vaccine mrna worldwide ongoing research global market
CureVac meldet Fortschritte in klinischen Phase-2-Entwicklungsprogrammen für COVID-19 und die saisonale Grippe in Zusammenarbeit mit GSK
Published: 2023-11-01 (Crawled : 13:00) - curevac.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -1.62%
H: 0.0%
C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -4.06%
H: 1.9%
C: 0.96%
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: 0.19%
H: 3.95%
C: -1.32%
covid-19 phase 2
CureVac veröffentlicht am 14. November 2023 Finanzergebnisse des dritten Quartals sowie der ersten neun Monate 2023 und informiert über seine Geschäftsentwicklung
Published: 2023-10-31 (Crawled : 15:30) - curevac.com
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.34%
H: 0.9%
C: 0.88%
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: -0.58%
H: 6.08%
C: 3.92%
CureVac berichtet über Fortschritt im Verfahren der Verletzung geistigen Eigentums gegen BioNTech in Deutschland
Published: 2023-09-28 (Crawled : 11:00) - curevac.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -3.04%
H: 2.1%
C: 2.1%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.94%
H: 0.44%
C: -0.95%
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: 2.53%
H: 1.99%
C: -10.84%
CureVac geht in Phase 2 der laufenden saisonalen Grippestudie in Zusammenarbeit mit GSK nach Auswahl eines vielversprechenden mRNA-Impfstoffkandidaten mit breiter Abdeckung
Published: 2023-09-12 (Crawled : 12:00) - curevac.com
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.16%
H: 0.09%
C: -0.27%
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: -0.47%
H: 0.62%
C: -3.79%
CureVac veröffentlicht Finanzergebnisse für das erste Quartal 2023 und informiert über seine Geschäftsentwicklung
Published: 2023-05-30 (Crawled : 11:00) - curevac.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -1.3%
H: 0.36%
C: 0.36%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: -1.28%
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: 0.0%
H: 1.64%
C: -3.06%
CureVac gibt Entwicklungen im Patentrechtsstreit mit Pfizer/BioNTech bekannt
Published: 2023-05-19 (Crawled : 11:00) - curevac.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -1.67%
H: 1.53%
C: 0.28%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.14%
H: 1.45%
C: 1.28%
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: 0.91%
H: 4.53%
C: 2.49%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: 0.37%
H: 1.96%
C: 1.09%
CureVac gibt Impfung des ersten Teilnehmers in kombinierter Phase 1/2-Studie für multivalente, modifizierte Grippe-Impfstoffkandidaten bekannt, entwickelt in Zusammenarbeit mit GSK
Published: 2023-05-08 (Crawled : 11:00) - curevac.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 4.81%
H: 0.0%
C: -6.12%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.24%
H: 0.3%
C: -0.81%
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: 0.0%
H: 4.98%
C: 2.55%
CureVac veröffentlicht Finanzergebnisse für das vierte Quartal sowie das Gesamtjahr 2022 und informiert über seine Geschäftsentwicklung
Published: 2023-04-25 (Crawled : 11:00) - curevac.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 0.22%
H: 4.05%
C: 4.05%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 1.64%
H: 0.19%
C: -0.91%
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: -1.3%
H: 2.24%
C: -4.35%
CureVac veröffentlicht am 25. April 2023 Finanzergebnisse des vierten Quartals sowie des Gesamtjahres 2022 und informiert über seine Geschäftsentwicklung
Published: 2023-04-18 (Crawled : 11:00) - curevac.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -6.76%
H: 3.18%
C: 1.34%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.64%
H: 0.23%
C: -1.0%
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: 0.13%
H: 1.13%
C: 0.0%
CureVac gibt Abschluss des öffentlichen Zeichnungsangebots mit Erlös von 250 Millionen US-Dollar bekannt
Published: 2023-02-10 (Crawled : 22:00) - curevac.com
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
| Email alert
Add to watchlist
GLAXF | $20.2 -14.18% 510
|
Health Technology
| Email alert
Add to watchlist
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
| Email alert
Add to watchlist
CureVac gibt Preisgestaltung des erhöhten öffentlichen Angebots von Stammaktien bekannt
Published: 2023-02-08 (Crawled : 02:00) - curevac.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 1.99%
H: 0.0%
C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 1.08%
H: 0.08%
C: -0.66%
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: 0.11%
H: 0.64%
C: -2.56%
CureVac kündigt geplantes Angebot von Stammaktien an
Published: 2023-02-06 (Crawled : 22:00) - curevac.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 3.77%
H: 0.0%
C: -1.96%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 1.84%
H: 0.5%
C: 0.5%
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: -6.62%
H: 1.11%
C: -5.06%
CureVac begrüßt Dr. Myriam Mendila als neuen Chief Development Officer
Published: 2023-02-01 (Crawled : 12:00) - curevac.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 1.91%
H: 0.0%
C: -1.42%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.0%
H: 1.5%
C: 0.65%
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: 0.74%
H: 8.96%
C: 8.96%
als
CureVac von LexisNexis® als einer der weltweit dynamischsten Innovatoren ausgezeichnet
Published: 2023-01-31 (Crawled : 13:20) - curevac.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 2.04%
H: 0.0%
C: -3.67%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.85%
H: 0.31%
C: -0.45%
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: -1.73%
H: 3.25%
C: -5.62%
lexisnexis als
CureVac veröffentlicht positive Daten bei älteren Erwachsenen aus COVID-19- und Grippe-mRNA-Impfstoffentwicklungsprogrammen
Published: 2023-01-30 (Crawled : 12:20) - curevac.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -2.59%
H: 3.12%
C: 1.79%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.74%
H: 0.2%
C: -1.24%
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: 5.36%
H: 4.0%
C: -3.5%
covid-19 positive
CureVac ernennt Alexander Zehnder zum Vorstandsvorsitzenden ab 1. April 2023
Published: 2023-01-09 (Crawled : 12:00) - curevac.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 1.9%
H: 0.0%
C: -1.81%
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 1.38%
H: 0.28%
C: 0.28%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.11%
H: 0.69%
C: -1.23%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.82%
H: 0.0%
C: 0.0%
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: 22.46%
H: 10.13%
C: 2.42%
CureVac gibt positive Daten aus gemeinsamen COVID-19- und Grippe-mRNA-Impfstoffentwicklungsprogrammen bekannt
Published: 2023-01-06 (Crawled : 12:20) - curevac.com
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.44%
H: 1.85%
C: 1.72%
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: 12.7%
H: 15.44%
C: 14.88%
covid-19 positive
CureVac-Mitglieder der Geschäftsleitung verkaufen Aktien zur Deckung steuerlicher Verpflichtungen aus Long Term Incentive Programm
Published: 2022-12-14 (Crawled : 22:00) - curevac.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -1.57%
H: 2.23%
C: 2.23%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.36%
H: 0.28%
C: -1.17%
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: -1.39%
H: 1.41%
C: -4.24%
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.